This story was originally posted on Aug. 1.
Affymetrix posted a 20 percent rise in second-quarter revenues last week, largely due to a contribution from its eBioscience business, but also driven by double-digit growth in genotyping array sales.
This article was originally posted on May 1.
An unanticipated decline in demand for gene expression microarrays has thwarted Affymetrix's return to growth and profitability and caused the firm to suspend its 2013 guidance, executives said last week.
The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.